Jason P Rhodes bought stock once, on Dec 12, 2022

Jason Rhodes is a corporate insider and director of Dyne Therapeutics, Inc. (NASDAQ: DYN), where he also serves as chairman of the board.( A longtime biotechnology company builder, he is a partner at Atlas Venture, focusing on the creation and development of novel therapeutics companies.( Rhodes was the founding CEO of Dyne Therapeutics and has played a central role in guiding the company from inception through its growth as a public biopharmaceutical firm.( He has recently reported insider transactions in Dyne shares in his capacity as a director and significant shareholder.(

Rhodes’ broader career includes senior leadership roles across multiple innovative life sciences companies. He was the founding CEO of Generation Bio and Rectify Pharmaceuticals, and the chair and founding CEO of Disarm Therapeutics, which was acquired by Eli Lilly.( He has served on or currently serves on boards including Replimune, Accent Therapeutics, K36 Therapeutics, AAVantgarde Bio, and others, and previously held executive positions at Epizyme—where he helped lead the company into the clinic and through a successful IPO—and at Alnylam Pharmaceuticals, where he led business development.( Earlier, he was a founder and partner at Fidelity Biosciences (now F-Prime Capital), overseeing investments in therapeutics companies such as FoldRx, later acquired by Pfizer.( Rhodes holds a B.A. from Yale University and an M.B.A. from the Wharton School of the University of Pennsylvania.(

Written by Perplexity from public sources.